Predictive Technology Group (PRED) Appoints John C. Nelson, M.D., M.P.H. to the Predictive Technology Group Scientific Advisory Board SALT LAKE CITY, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group...

Mesoblast Phase 3 Program For Degenerative Disc Disease To Include European Sites After Positive Meeting With European Medicines Agency NEW YORK and MELBOURNE, Australia, April 7, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that following positive feedback from its recent meeting with the...

Boardroom Radio Interview with Mesoblast Chief Executive NEW YORK, Feb. 2, 2014 (GLOBE NEWSWIRE) -- Audio link - http://www.brrmedia.com/event/120127BRR    Today at Boardroom Radio (BRR) we're once again joined by Mr Silviu Itescu, who is...

MESOBLAST REPORTS POSITIVE INTERIM RESULTS IN PHASE 2 TRIAL OF PROPRIETARY ADULT STEM CELLS FOR INTERVERTEBRAL DISC REPAIR Mesoblast's Phase 2 trial of allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs) injected into damaged intervertebral discs has now completed six-month follow-up for all 100...